4.33
-0.245(-5.36%)
Currency In USD
| Previous Close | 4.57 |
| Open | 4.74 |
| Day High | 4.74 |
| Day Low | 4.31 |
| 52-Week High | 5.14 |
| 52-Week Low | 0.64 |
| Volume | 59,637 |
| Average Volume | 2.12M |
| Market Cap | 19.73M |
| PE | -3.38 |
| EPS | -1.28 |
| Moving Average 50 Days | 3.72 |
| Moving Average 200 Days | 2.13 |
| Change | -0.25 |
If you invested $1000 in Lixte Biotechnology Holdings, Inc. (LIXT) 10 years ago, it would be worth $277.24 as of September 09, 2025 at a share price of $4.325. Whereas If you bought $1000 worth of Lixte Biotechnology Holdings, Inc. (LIXT) shares 5 years ago, it would be worth $60.07 as of September 09, 2025 at a share price of $4.325.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor
Newsfile
Sep 05, 2025 12:35 PM GMT
Unlocking a New Era in Cancer TreatmentDenver, Colorado--(Newsfile Corp. - September 5, 2025) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, underscores the scie
LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer
GlobeNewswire Inc.
Sep 03, 2025 12:00 PM GMT
Peter Stazzone Chief Financial Officer, LIXTE Biotechnology Holdings Lourdes Felix Board of Directors, LIXTE Biotechnology Holdings Guy Primus Board of Directors, LIXTE Biotechnology Holdings -- Company Relocates Corporate Headquarters to
24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy
GlobeNewswire Inc.
Aug 27, 2025 12:15 PM GMT
New Peer-Reviewed Publication Highlights Landmark Meeting Co-Sponsored by LIXTEDENVER, Aug. 27, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate inform